ReviewJournal of translational medicine2026
Application of melanin and its engineered nanomaterials in tumor radiotherapy: a review.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundRadiotherapy (RT) is the cornerstone of cancer treatment, but its clinical efficacy is frequently hampered by radiation-induced damage to normal tissues and the radioresistance of tumors. As a natural biopolymer, melanin demonstrates the potential for a bidirectional role in radioprotection and radiosensitization due to its unique physicochemical properties. MAIN CONTENT: This review systematically analyzes the bidirectional roles of melanin and engineered melanin nanomaterials (EMNMs) in tumor RT. Under physiological conditions, melanin predominantly functions as a radioprotector by absorbing radiation, scavenging reactive oxygen species (ROS), chelating metal ions, and regulating redox states. Conversely, in pigmented tumors such as melanoma, melanin overproduction leads to RT resistance. This resistance is driven by mechanisms including the “ROS sponge” effect, hypoxia induction, metabolic reprogramming, and interference with immune activation. To circumvent RT resistance, research strategies have expanded from inhibiting melanin synthesis to its functional engineering. Through synthetic biology and nanotechnology, melanin—especially melanin-like substances such as polydopamine (PDA)—can be atomically doped, structurally designed, and functionally loaded to construct multifunctional nanoplatforms. Consequently, these EMNMs can convert RT resistance into RT sensitization by enhancing physical energy deposition, catalyzing chemical reactions, regulating the hypoxic tumor microenvironment (TME), and synergizing with immunotherapy (IT). Furthermore, their utility can be extended to broad-spectrum sensitization applications in non-pigmented tumors.
conclusionMelanin and EMNMs are emerging as highly promising platforms for realizing “bidirectional precision RT” (i.e., targeted tumor eradication concurrent with precise normal tissue preservation) and broad-spectrum RT sensitization. Future challenges lie in developing intelligent responsive materials and systematically evaluating their long-term biosafety, ultimately driving the clinical translation of personalized RT sensitization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.